A Panel of Novel Biomarkers Representing Different Disease Pathways Improves Prediction of Renal Function Decline in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We aimed to identify a novel panel of biomarkers predicting renal function decline in type 2 diabetes, using biomarkers representing different disease pathways speculated to contribute to the progression of diabetic nephropathy. RESEARCH DESIGN AND METHODS: A systematic data integration approach was used to select biomarkers representing different disease pathways. Twenty-eight biomarkers were measured in 82 patients seen at an outpatient diabetes center in The Netherlands. Median follow-up was 4.0 years. We compared the cross-validated explained variation (R2) of two models to predict eGFR decline, one including only established risk markers, the other adding a novel panel of biomarkers. Least absolute shrinkage and selection operator (LASSO) was used for model estimation. The C-index was calculated to assess improvement in prediction of accelerated eGFR decline defined as <-3.0 mL/min/1.73m2/year. RESULTS: Patients' average age was 63.5 years and baseline eGFR was 77.9 mL/min/1.73m2. The average rate of eGFR decline was -2.0 ± 4.7 mL/min/1.73m2/year. When modeled on top of established risk markers, the biomarker panel including matrix metallopeptidases, tyrosine kinase, podocin, CTGF, TNF-receptor-1, sclerostin, CCL2, YKL-40, and NT-proCNP improved the explained variability of eGFR decline (R2 increase from 37.7% to 54.6%; p=0.018) and improved prediction of accelerated eGFR decline (C-index increase from 0.835 to 0.896; p=0.008). CONCLUSIONS: A novel panel of biomarkers representing different pathways of renal disease progression including inflammation, fibrosis, angiogenesis, and endothelial function improved prediction of eGFR decline on top of established risk markers in type 2 diabetes. These results need to be confirmed in a large prospective cohort.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple imputation using chained equations: Issues and guidance for practice
White, I. R., Royston, P., & Wood, A. M. (2011) · Statistics in Medicine · doi:10.1002/sim.4067 · Cited by 9,792 · cited 1×
“Variables with missing values were multiply imputed using chained equations [16].”
MethodClinical Prediction Models: A Practical Approach to Development, Validation, and Updating
Steyerberg, E. W. (2019) · Statistics for Biology and Health · doi:10.1007/978-3-030-16399-0 · Cited by 3,281
Changes in diabetes-related complications in the United States, 1990-2010
Gregg, E. W., Li, Y., Wang, J., Rios Burrows, N., Ali, M. K., Rolka, D., Williams, D. E., & Geiss, L. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310799 · Cited by 1,749 · cited 1×
“Type 2 diabetes is the leading cause of chronic kidney disease (CKD) in the United States and is associated with high cardiovascular risk [1, 2].”
BackgroundAlbuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes
Ninomiya, T., Perkovic, V., de Galan, B. E., Zoungas, S., Pillai, A., Jardine, M., Patel, A., Cass, A., Neal, B., Poulter, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008121270 · Cited by 965
Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease
Sharma, K., Karl, B., Mathew, A. V., Gangoiti, J. A., Wassel, C. L., Saito, R., Pu, M., Sharma, S., You, Y.-H., Wang, L., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013020126 · Cited by 571 · cited 1×
“Furthermore, a panel of 13 metabolites linked with mitochondrial metabolism was significantly reduced in CKD patients with diabetes compared to healthy controls [38], and the combination of plasma metabolites butenoylcarnitine and histidine, and urine metabolites glutamine, tyrosine, and hexoses were able to predict t…”
BackgroundMapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy
Fechete, R., Heinzel, A., Perco, P., Mönks, K., Söllner, J., Stelzer, G., Eder, S., Lancet, D., Oberbauer, R., Mayer, G., et al. (2011) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201000136 · Cited by 45 · cited 2×
“However, because type 2 diabetes is a multifactorial disease, several pathways involving pro-inflammatory, pro-fibrotic, and angiogenic processes, among others, are activated during the course of the disease [7].”
BackgroundMethodSelf-citation
Cited by
Biomarkers of diabetic kidney disease
Colhoun, H. M., & Marcovecchio, M. L. (2018) · Diabetologia · doi:10.1007/s00125-018-4567-5 · Cited by 270
Pugliese, G., Penno, G., Natali, A., Barutta, F., Di Paolo, S., Reboldi, G., Gesualdo, L., & De Nicola, L. (2019) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.07.017 · Cited by 156
Role of MCP-1 as an inflammatory biomarker in nephropathy
Liu, Y., Xu, K., Xiang, Y., Ma, B., Li, H., Li, Y., Shi, Y., Li, S., & Bai, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1303076 · Cited by 93
Glazyrin, Y. E., Veprintsev, D. V., Ler, I. A., Rossovskaya, M. L., Varygina, S. A., Glizer, S. L., Zamay, T. N., Petrova, M. M., Minic, Z., Berezovski, M. V., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134802 · Cited by 35
“The distinct changes in the expression of individual proteins, such as monocyte chemoattractant protein-1 (MCP-1) and transforming growth factor-β1 (TGF-β1) [28], or even in panels of several proteins [29] noted previously as predicting the rate of renal function decline in diabetes, may also be accompanied by other m…”
Background
Metadata
- Authors
- Pena, M. J., Heinzel, A., Heinze, G., Alkhalaf, A., Bakker, S. J. L., Nguyen, T. Q., Goldschmeding, R., Bilo, H. J. G., Perco, P., Mayer, B., de Zeeuw, D., & Lambers Heerspink, H. J.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-05-14
- Volume
- 10
- Issue
- 5
- Pages
- e0120995
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2131474777
- Cited by
- 66
- References
- 6
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.